Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Bristol-Myers Squibb
Astellas Pharma Inc
PMV Pharmaceuticals, Inc
Genmab
Tizona Therapeutics, Inc
Essen Biotech
Eli Lilly and Company
Takeda
Eli Lilly and Company
Daiichi Sankyo
Astellas Pharma Inc
Memorial Sloan Kettering Cancer Center
Turnstone Biologics, Corp.
Intensity Therapeutics, Inc.
RAPT Therapeutics, Inc.
Carisma Therapeutics Inc
Eli Lilly and Company
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
Celldex Therapeutics
Ikena Oncology
Ikena Oncology
Atreca, Inc.
Corvus Pharmaceuticals, Inc.
Fate Therapeutics
Kineta Inc.
M.D. Anderson Cancer Center
Fate Therapeutics
Silverback Therapeutics
Silverback Therapeutics
Incyte Corporation
Seagen Inc.
Western Regional Medical Center